Data from the survival outcomes of patients support the use of active surveillance in low risk and intermediate risk cases of Gleason 6 but not Gleason 7 prostate cancer. Multiparametric magnetic resonance imaging and novel biomarkers might be vital in detecting favorable Gleason 7 disease. Read the article here.
Predicting outcomes on active surveillance for intermediate-risk patients Read the article here. Active Surveillance for Intermediate-risk Prostate Cancer Challenged Read the article here. Active Surveillance versus Watchful Waiting Read the article here. Surgery isn’t necessarily best for prostate cancer, according to study led by Minneapolis VA Read the article here.